Search results
Novavax Seeks FDA Nod for Updated COVID-19 Vaccine - Novavax (NASDAQ:NVAX), Moderna (NASDAQ:MRNA)
Benzinga· 4 days agoNovavax's filing is based on guidance from the FDA issued last week, which advised COVID-19 vaccine...
The FDA Now Wants Fall COVID Vaccines to Target KP.2—But Not All Manufacturers Can Pivot
Verywell Health via Yahoo News· 2 days agoLess than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall,...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoModerna says it has finished dosing healthy participants in a Phase 1 and Phase 2 study of its...
Moderna Just Gave Investors Another Reason to Buy the Stock
The Motley Fool via AOL· 6 days agoThis technology was unproven until 2020 (no mRNA-based vaccine had been approved or granted...
Gateway - Quartz
Quartz· 4 days agoModerna said Tuesday that its updated COVID-19 vaccine demonstrated a stronger immune response than its current jab in results from a ...
COVID-19 is surging. Time to mask up or get a booster? What a Boise medical expert says
Idaho Statesman McClatchy via AOL· 2 days agoThe Centers for Disease Control and Prevention recommends everyone 6 months and older get an updated...
COVID summer wave grows, especially in West, with new variant LB.1 on the rise
CBS News· 1 day agoA summertime wave of COVID-19 infections is arriving earlier than last year across a growing share...
Feeling Sick After Your COVID Vaccine? According to Scientists, It’s Actually a Good Sign
SciTechDaily· 3 days agoA UCSF study suggests that side effects like headaches and chills from COVID-19 vaccines indicate a...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoThe company also unveiled promising results in people age 18 to 59 years old with underlying...
...NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation...
NewMediaWire via Yahoo Finance· 4 days ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, ...